Journal of Clinical Pathways’ Post

In this interview, Alex Spira, MD, PhD, FACP, FASCO, discussed post-progression results from the phase 3 MARIPOSA-2 trial, which showed that amivantamab plus chemotherapy prolonged time to treatment discontinuation and time to subsequent therapy in patients with EGFR-mutated NSCLC. "We believe this will present a new standard after disease progression on osimertinib," said Dr Spira. Check out the full video here: https://lnkd.in/ebVwQnuu #JournalOfClinicalPathways #NonSmallCellLungCancer #NSCLC #ClinicalTrial 

Amivantamab Plus Chemotherapy Improved Treatment Outcomes Among Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Amivantamab Plus Chemotherapy Improved Treatment Outcomes Among Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer

hmpgloballearningnetwork.com

To view or add a comment, sign in

Explore topics